June 17, 2026
Defence Therapeutics Inc.
ISIN: CA24463V1013
Defence Therapeutics to Participate in BIO International Convention 2026 Next Week for Strategic Partnership Discussions
Montreal, QC, Canada, June 17th, 2026 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is...
Read more >>Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using its Proprietary Accum Technology
Montreal, QC, Canada, November 19th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs current limitations. Following successful presentations and meetings at the...
Read more >